Q1 2025 13F Holders as of 31 Mar 2025
-
Type / Class
-
Equity / Common Shares, with no par value
-
Shares outstanding
-
50,973,571
-
Number of holders
-
11
-
Total 13F shares, excl. options
-
2,167,593
-
Shares change
-
+341,323
-
Total reported value, excl. options
-
$7,087,336
-
Value change
-
+$1,118,946
-
Number of buys
-
8
-
Number of sells
-
4
-
Price
-
$3.28
Institutional Holders of EUPRAXIA PHARMACEUTICALS INC. - Common Shares, with no par value (EPRX) as of Q1 2025
As of 31 Mar 2025 EUPRAXIA PHARMACEUTICALS INC. - Common Shares, with no par value (EPRX) had 11 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions held a total of 2,167,593 shares of stock of the company.
Largest 10 holders included SCOTIA CAPITAL INC., ROYAL BANK OF CANADA, TD Waterhouse Canada Inc., BANK OF MONTREAL /CAN/, UBS Group AG, GOLDMAN SACHS GROUP INC, CITADEL ADVISORS LLC, RAYMOND JAMES FINANCIAL INC, JPMORGAN CHASE & CO, and BANK OF AMERICA CORP /DE/.
This table shows 11 institutional shareholders of the security as of 31 Mar 2025.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.